Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency
September 15, 2023 08:00 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the launch in Germany of SKYTROFA® (lonapegsomatropin), its growth hormone approved in the...
Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism
September 14, 2023 12:22 ET
|
Ascendis Pharma
- Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024 COPENHAGEN, Denmark, Sept. 14, 2023...
Ascendis Pharma Reports Second Quarter 2023 Financial Results
September 05, 2023 16:03 ET
|
Ascendis Pharma
Expect to resubmit NDA to FDA for TransCon™ PTH in October 2023; EC decision on MAA for TransCon PTH expected during the fourth quarter of 2023U.S. and EU regulatory authorities endorsed ApproaCH as a...
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
September 05, 2023 16:01 ET
|
Ascendis Pharma
- Proceeds to support continued development and commercialization of Endocrine Rare Disease products, and general corporate purposes COPENHAGEN, Denmark and NEW YORK, Sept. 05, 2023 (GLOBE...
New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism
September 05, 2023 16:01 ET
|
Ascendis Pharma
- Approximately 50% of Phase 3 PaTHway Trial patients with eGFR < 60 mL/min/1.73m2, the threshold for kidney dysfunction, receiving TransCon PTH experienced eGFR improvement to above 60...
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
August 24, 2023 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice...
Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023
August 15, 2023 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on...
One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
June 17, 2023 17:30 ET
|
Ascendis Pharma
- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously reported for the initial 26-week blinded portion of the...
Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023
June 13, 2023 07:00 ET
|
Ascendis Pharma
- Endocrinology clinical development progress and research in growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome will be highlighted - Phase 3 Week 52 data for...
Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice...